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ABSTRACT
Introduction: To assess the impact on
hospitalization costs of multimodal analgesia
(MMA), including intravenous acetaminophen
(IV-APAP), versus IV opioid monotherapy for
postoperative pain management in patients
undergoing orthopedic surgery.
Methods: Utilizing the Truven Health
MarketScan Hospital Drug Database (HDD),
patients undergoing total knee arthroplasty
(TKA), total hip arthroplasty (THA), or surgical
repair of hip fracture between 1/1/2011 and
8/31/2014 were separated into postoperative
pain management groups: MMA with IV-APAP
plus other IV analgesics (IV-APAP group) or an
IV opioid monotherapy group. All patients
could have received oral analgesics. Baseline
characteristics and total hospitalization costs
were compared. Additionally, an inverse
probability treatment weighting [IPTW] with
propensity scores analysis further assessed
hospitalization cost differences.
Results: The IV-APAP group (n = 33,954) and
IV opioid monotherapy group (n = 110,300)
differed significantly (P\0.0001) across
baseline characteristics, though the differences
may not have been clinically meaningful. Total
hospitalization costs (mean ± standard
deviation) were significantly lower for the
IV-APAP group than the IV opioid
monotherapy group (US$12,540 ± $9564 vs.
$13,242 ± $35,825; P\0.0001). Medical costs
accounted for $701 of the $702 between-group
difference. Pharmacy costs were similar between
groups. Results of the IPTW-adjusted analysis
further supported the statistically significant
cost difference.
Conclusions: Patients undergoing orthopedic
surgery who received MMA for postoperative
pain management, including IV-APAP, had
significantly lower total costs than patients
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who received IV opioid monotherapy. This
difference was driven by medical costs;
importantly, there was no difference in
pharmacy costs. Generalizability of the results
may be limited to patients admitted to hospitals
similar to those included in HDD. Dosing could
not be determined, so it was not possible to
quantify utilization of IV-APAP or ascertain
differences in opioid consumption between
the 2 groups. This study did not account for
healthcare utilization post-discharge.
Keywords: Hospitalization costs; Intravenous
acetaminophen; IV opioid monotherapy;
Multimodal analgesia; Orthopedic surgery;
Postoperative analgesia; Triple aim
INTRODUCTION
The Institute for Healthcare Improvement (IHI)
Triple Aim requires simultaneous pursuit of (1)
improving the patient care experience, (2)
advancing population health, and (3) reducing
per capita costs of healthcare [1, 2]. In the
context of postoperative pain management,
current practice guidelines and
recommendations from professional groups
and agencies across disciplines such as the
American Academy of Orthopaedic Surgeons
[3, 4], American Society of Anesthesiologists [5],
American College of Critical Care Medicine [6],
American Pain Society [7], American Society for
Pain Management Nursing [8], Joint
Commission [9, 10], and Agency for
Healthcare Research and Quality [11] support
the use of multimodal analgesia (MMA), which
is defined as the use of multiple analgesic
medications and nondrug interventions
targeting different peripheral or central
nervous system sites in the pain pathway [7].
This approach follows the rationale that use of
multiple medications may provide additive, or
possibly synergistic, analgesic effects compared
with a single agent [7]. The goal of MMA is to
improve pain control and, by reducing dose
levels of any 1 medication, ameliorate side
effects [12]. Clinical trials have demonstrated
superior pain control and reduced consumption
of opioids, as administered via
patient-controlled analgesia, with MMA
compared with single-agent pain therapy
[13, 14]. Despite the increased intensity of
pain management intervention associated with
MMA, it may reduce medical costs by
improving postoperative clinical outcomes and
shortening length of stay (LOS) [15].
In addition to other widely used pain
medications, including opioids, nonsteroidal
anti-inflammatory drugs (NSAIDs) (used as
early as the 1960s [16]) and some neurologic
agents (e.g., gabapentin and pregabalin),
acetaminophen (APAP), a centrally-acting
analgesic agent, is commonly employed in
postoperative MMA [7, 17]. In certain patients,
including those for whom use of NSAIDs may be
inadvisable or contraindicated (e.g., patients
with certain cardiac diseases or who have
undergone coronary artery bypass graft
surgery) [6, 18–20], APAP has been used
postoperatively. Oral APAP has been available
since 1951 [21]. However, the oral formulation
does not meet the needs of all postoperative
patients, including those who cannot take oral
drugs because of nausea, vomiting, or slow
recovery of gastrointestinal function and those
whose exposure to opioids or anesthesia during
surgery may have impaired drug absorption
sufficiently to preclude effective analgesia by
the oral route. The intravenous formulation of
APAP (IV-APAP) was first approved in the
United States (US) in 2010 for the
management of mild to moderate pain,
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management of moderate to severe pain with
adjunctive opioid analgesics, and reduction of
fever and is currently available as a branded
product [21]. Besides enabling APAP analgesia
in patients who are unable to take the
medication orally, IV-APAP offers more
efficient and reliable delivery of therapeutic
doses than do the oral and rectal forms
[17, 22, 23]. Compared with either oral or
rectal administration at similar dose levels,
IV-APAP yields quicker and higher peak
plasma and cerebrospinal drug concentrations
[17].
In randomized clinical trials conducted in
the US, IV-APAP use in surgical patients has
demonstrated analgesic efficacy as evaluated
through assessments of pain and pain relief
and measurements of opioid consumption,
with a favorable safety and tolerability profile
[24–27]. More recently, IV-APAP’s efficacy,
opioid-sparing benefits, and safety in
postoperative pain management were
confirmed in a Cochrane Collaboration
systematic review comprising 75 studies
conducted in Africa, Australia, Asia, the US,
and Europe [28]. Randomized clinical trials of
IV-APAP have also yielded evidence of
improved patient satisfaction [29].
The orthopedic surgical procedures total
knee arthroplasty (TKA), total hip arthroplasty
(THA), and hip repair rank among the 12 most
commonly performed inpatient surgical
procedures in the US, together accounting for
more than 1.4 million hospital stays annually,
according to the most recent data (2012) from
the Healthcare Cost and Utilization Project [30].
Consequently, the costs, or cost savings,
associated with treatment interventions in this
orthopedic surgery subpopulation can have
important economic implications for
healthcare institutions. To assess the
hospitalization cost impact of MMA including
IV-APAP, an exploratory analysis of patients in a
US hospital database who underwent TKA, THA,
or hip repair was conducted to compare costs in
patients receiving IV-APAP and other IV
analgesics as part of MMA, with those
receiving IV opioid monotherapy.
METHODS
Study Design
This was a retrospective observational analysis
of patients who underwent inpatient elective
orthopedic surgery at US hospitals that
contribute billing data to a national hospital
database. This article is based on previously
collected data and does not involve any new
data collection of human or animal subjects
performed by any of the authors.
Data Source
Data were obtained from the MarketScan
Hospital Drug Database (HDD) (Truven Health
Analytics, Ann Arbor, MI, USA). The HDD
contains data from the billing systems of
approximately 600 participating hospitals,
which represent approximately 11% of all US
hospitals [31]. Each record represents an
inpatient admission and discharge and
includes detailed information on patient
demographics, provider specialty, diagnoses,
procedures, drug administration, and facility
charges. All services recorded by the hospital
and all admissions, regardless of the patient’s
insurance status, are captured. Data are updated
monthly with the majority of hospitals
reporting discharges at a 45-day lag after the
close of the month.
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Study Population
Patients 18 years of age or older who underwent
elective TKA, THA, or surgical repair of hip
fracture, as indicated by the principal
International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM)
procedure code or the Current Procedural
Terminology (CPT) code from the index
hospitalization (see ‘‘Appendix’’, Table 3 for
codes), were identified. Patients were required
to have discharge disposition coded as ‘‘home’’
or ‘‘other eligible facility’’ (e.g., other self-care
facility, short-term care facility, or home health
services). Patients who had evidence of
substance abuse disorder (see ‘‘Appendix’’,
Table 3) or who used methadone or
buprenorphine during the index
hospitalization were excluded. Also excluded
were patients who underwent more than 1
surgery of interest during the same
hospitalization.
Study Cohorts
Patients were categorized by the postoperative
pain management regimen received: a
combination of IV-APAP plus other analgesics
(which could include both IV and oral
analgesics) (IV-APAP group) or IV opioid
monotherapy (IV opioid monotherapy group).
Patients who also received IV NSAIDs were
excluded from the IV opioid group, as this
group was intended to represent patients
receiving monotherapy with IV opioids.
Patients in either cohort could have also
received oral analgesics (e.g., hydromorphone,
oxycodone, hydrocodone, NSAIDs) as part of
the postoperative pain management regimen.
To be eligible, patients had to have started IV
analgesia on postoperative day 0 (i.e., the same
day as surgery).
Variables
The following data from the HDD were
included in this analysis: patient
demographics, geographic region, payer type,
hospital size, setting type, teaching status, and
year of surgical procedure. Cost data included
total hospitalization costs, which comprised
medical costs and pharmacy costs. Medical
costs included medical/surgical supplies,
laboratory, imaging, and other costs (including
room and board, operating room, therapy/
respiratory therapy, and miscellaneous/routine
costs). Costs were analyzed for the index
admission only and were adjusted to 2014 US
dollars using the medical component of the
Consumer Price Index (United States
Department of Labor). Costs represent what it
costs the hospital to provide care to the patient,
independent of insurance type or status.
Statistical Analysis
Descriptive statistics were used to characterize
the study sample during the baseline period and
to compare treatment groups in terms of
demographic, payer, and hospital
characteristics. Differences in categorical
variables were assessed using the Chi square
test, while differences in continuous variables
(including unadjusted differences in
hospitalization costs) were assessed using the
Student’s t test. The a priori statistical
significance level was set at a = 0.05.
In the adjusted analysis of hospitalization
costs, inverse probability treatment weighting
(IPTW) with propensity scores was used to
account for potential confounding while
retaining the entire sample of patients. The
propensity score was defined as the probability
of being treated with IV-APAP, conditional on
the individual’s baseline characteristics (age at
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index admission, year of index admission, and
index payer), and the score was derived from a
logistic regression model. A weight was then
calculated for each individual as the inverse of
the individual’s propensity score [32]. These
weights were used to create a synthetic sample
in which the distribution of measured baseline
covariates was independent of treatment
assignment. This adjusted analysis controlled
for age, gender, region, payer, year of index




Figure 1 summarizes the selection of eligible
patients from the entire population of patients
who underwent the selected elective orthopedic
proceduresduring theenrollmentperiodandwho
received IV-APAP as part of an MMA regimen or
who received IV opioid monotherapy. In the
IV-APAP group, the most common other IV
analgesics received were fentanyl,
hydromorphone, and morphine while the most
common oral analgesics received were celecoxib,
hydrocodone, and tramadol (see ‘‘Appendix’’,
Tables 4 and 5). The final sample comprised
33,954 patients who received IV-APAP as part of
MMA and 110,300 who received IV opioid
monotherapy.
Patient Demographic, Payer, and Hospital
Characteristics
Patient demographic, payer, and hospital
characteristics are shown in Table 1. Statistically
significant differences between treatment groups
were noted for all baseline characteristics.
However, the large sample sizes confer greater
likelihood of attaining statistically significant
differences, irrespective of whether numerical
differences observed are meaningful in clinical
or practical terms [33]. Standardized differences
for these baseline characteristics are also included
in Table 1. A standardized difference of 10% (or
0.1) is considered equivalent to a P value of 0.05,
indicating insignificant correlation [34]. The only
readily discerned noteworthy difference between
the treatment groups was that patients in the
IV-APAP group tended to have had admissions
during the latter2 yearsof the studyperiod; in this
group, 65.1% of index admissions occurred in
2013 or 2014, compared with 33.2% in the IV
opioid monotherapy group.
Unadjusted total,medical, andpharmacycosts
for the IV-APAP and IV opioid monotherapy
groups are shown in Table 2. Total mean
[±standard deviation (SD)] hospitalization cost
was significantly lower (P\0.0001) for patients in
the IV-APAP group comparedwith those in the IV
opioid monotherapy group ($12,540± $9564 vs.
$13,242 ± $35,825), which represents an
approximately $702 lower total cost for the
IV-APAP group. The difference in total costs was
almost completely accounted for by medical
costs, which were $701 lower in the IV-APAP
group than in the IV opioid monotherapy group
(P\0.0001). Within the medical cost category,
the largest between-group absolute differencewas
in ‘‘other’’ costs (room and board, operating room
costs, therapy and respiratory therapy costs, and
miscellaneous/routine costs), which were $571
lower for the IV-APAPgroup (P\0.0001).Ofnote,
pharmacy costs were comparable between the
treatment groups ($486 for the IV-APAP group
and $488 for the IV opioid monotherapy group).
In the adjusted analysis using IPTW with
propensity scores, total hospitalization costs
(Fig. 2) were consistent with the unadjusted
analysis, with the IV-APAP group having $830
lower total costs than the IV opioid
monotherapy group (P\0.0001).
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DISCUSSION
In this retrospective observational analysis of
more than 140,000 hospital admissions for TKA,
THA, or hip fracture repair, costs for patients
receiving postoperative MMA with a
combination of IV-APAP plus other IV
analgesics were compared with costs for
patients who received IV opioid monotherapy
starting on the day of surgery. Total mean
hospitalization costs were significantly lower,
by $702, for the IV-APAP group than for the IV
Fig. 1 Study sample selection and exclusion criteria. IV intravenous, IV-APAP intravenous acetaminophen, NSAID
nonsteroidal anti-inﬂammatory drug
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opioid monotherapy group. This cost difference
was driven almost exclusively by medical costs,
particularly ‘‘other’’ medical costs, which
included room and board, operating room,
therapy/respiratory therapy, and
miscellaneous/routine costs. Pharmacy costs
for the 2 groups were comparable. The
treatment groups differed at baseline; however,
an adjusted analysis using IPTW weighting with
propensity scores confirmed the findings in







Age in years (mean, SD) 62.1 12.1 61.4 12.5 \0.0001 0.0569
Female (n, %) 19,151 56.4 60,787 55.1 \0.0001 0.0260
Year of index admission (n, %) \0.0001
2011 2420 7.1 40,729 36.9 –0.7705
2012 9427 27.8 32,973 29.9 –0.0470
2013 13,335 39.3 24,252 22.0 0.3818
2014 8772 25.8 12,346 11.2 0.3838
Payer (n, %) \0.0001
Commercial/private 8234 24.3 29,898 27.1 –0.0654
Medicaid 1914 5.6 5189 4.7 0.0421
Medicare 15,300 45.1 49,252 44.7 0.0082
Self-pay 423 1.2 1227 1.1 0.0124
Other 8083 23.8 24,734 22.4 0.0328
Geographic region (n, %) \0.0001
Midwest 5772 17.0 21,032 19.1 –0.0538
East 713 2.1 9089 8.2 –0.2800
South 20,802 61.3 64,917 58.9 0.0492
West 6667 19.6 15,262 13.8 0.1558
Hospital size, beds (n, %) \0.0001
1–199 8796 25.9 19,751 17.9 0.1943
200–299 5106 15.0 17,287 15.7 –0.0176
300–499 11,119 32.7 39,402 35.7 –0.0627
500? 8933 26.3 33,860 30.7 –0.0973
Hospital type (n, %) \0.0001
Rural 2235 6.6 12,883 11.7 –0.1777
Urban 31,719 93.4 97,417 88.3 0.1777
Hospital teaching status (n, %) \0.0001
Non-teaching 28,329 83.4 92,206 83.6 –0.0044
Teaching 5625 16.6 18,094 16.4 0.0044
APAP acetaminophen, IV intravenous, SD standard deviation
a Patients in the IV-APAP group received a combination of IV-APAP plus other analgesics
b P value for comparison based on a t test for continuous variables and a Chi square test for categorical variables
c Standardized difference equals the difference in means/proportions divided by standard error, with an imbalance deﬁned as absolute
value[0.10
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hospitalization cost differences seen in the
initial, unadjusted analysis.
As the acquisition cost of IV-APAP is higher,
the economic implications of its utilization have
been of interest to healthcare institutions and
systems [35]. In the absence of economic data
from prospective studies, retrospective
pharmacoeconomic analyses and modeling
have been conducted to estimate overall cost
impact in surgical patient subpopulations. The
current study contributes novel health
economic data on the use of IV-APAP as part of
postoperative MMA from a large population of
surgical patients receiving care at a diverse group
of approximately 600 participating hospitals
throughout the US. Use of a database derived
from hospital billing records enables a
comprehensive analysis of inpatient costs for
both patients receivingMMA including IV-APAP
and those receiving IV opioid monotherapy.
Furthermore, these study results are in
agreement with previous research, while
providing additional real-world evidence to
help inform population health decision
makers and healthcare providers about the
health economic benefits of IV-APAP as part of
MMA in the context of treatment protocols and
medical policy development. For example, a
recent hospital database analysis of patients
who received combination IV-APAP plus IV
opioids (n = 174,805) with those who received
IV opioid monotherapy (n = 311,090) [36]
corroborate the current study findings of
significantly lower hospitalization costs for the
patients who received IV-APAP. Another
hospital database analysis of patients who
underwent elective major joint arthroplasty
found that patients who received IV-APAP had
total hospitalization costs that were
significantly lower than similar patients who
did not receive IV-APAP [37]. While the current
analysis did not allow for the elucidation of the
factors underlying reduced hospitalization cost
in IV-APAP-treated patients, previous analyses
have found reduced LOS for such patients [36]
and significantly fewer adverse events [37].
A possible cost factor more directly related to
use of IV-APAP is opioid consumption [38].
Table 2 Total hospitalization, medical, and pharmacy costs, IV-APAP group and IV opioid monotherapy group





Total $12,540 $9564 $13,242 $35,825 \0.0001
Medicalc $12,053 $9377 $12,754 $34,870 \0.0001
Medical/surgical supplies $2795 $1870 $2889 $5717 \0.0001
Laboratory $197 $301 $219 $1019 \0.0001
Imaging $91 $129 $105 $238 \0.0001
Otherd $8970 $7922 $9541 $30,735 \0.0001
Pharmacy $486 $488 $488 $1120 0.6786
APAP acetaminophen, IV intravenous, SD standard deviation
a Patients in the IV-APAP group received a combination of IV-APAP plus other analgesics
b P value for comparison based on a t test for continuous variables
c Medical costs = medical/surgical supplies costs ? lab costs ? imaging costs ? other costs
d Other costs include room and board, operating room costs, therapy and respiratory therapy costs, and miscellaneous/
routine costs
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Although the average dose or number of doses
of IV-APAP or opioids was not evaluated in the
presented study, the benefit of IV-APAP in
reducing opioid consumption was confirmed
in a recent Cochrane Collaboration systematic
review and meta-analysis of randomized,
double-blind, controlled, single-dose clinical
trials of IV-APAP or IV propacetamol for acute
postoperative pain in adults or children (75
trials involving 7200 patients) [28]. Patients
receiving IV-APAP or IV propacetamol used
approximately 26% fewer opioids (reported as
morphine equivalents) over 4 h and 16% fewer
opioids over 6 h than did patients assigned to
placebo.
Reduction in morphine requirement with
use of IV-APAP formed the basis of a recent
pharmacoeconomic modeling study [38]. The
study derived data from de-identified records
from more than 2 million inpatient surgical
encounters at 297 hospitals, including more
than 270,000 in which use of IV-APAP was
documented. The results indicate that use of
IV-APAP and reduction in morphine
Fig. 2 Total costs for IV-APAP group and IV opioid
monotherapy group, based on adjusted analysis using
IPTW with propensity scores. CI conﬁdence interval, IV
intravenous, IV-APAP intravenous acetaminophen, IPTW
inverse probability treatment weighting. Note: patients in
the IV-APAP group received a combination of IV-APAP
plus other analgesics. P value was obtained from the IPTW
with propensity score analysis output
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requirement by 1 level (from high to medium,
medium to low, or low to none) together
reduced rates of opioid-related complications,
LOS, and costs for various surgery types. For
example, for knee replacement, the calculated
reduction in LOS with use of IV-APAP and
reduction of morphine requirement by 1 level
was 0.77 days, and annual reduction in
LOS-associated costs was $460,000 from a
medium-sized hospital perspective (100–399
beds). Additional cost savings accrued from a
nearly 29% decrease in opioid-related
complications with the use of IV-APAP and
reduced opioid requirement.
In this study, patients in the IV-APAP group
may also have received other IV analgesics
along with IV-APAP as part of postoperative
MMA (see ‘‘Appendix’’, Table 4 for details on
other IV analgesics received), reflecting
real-world clinical practices. The findings of
the current study support the health economic
benefit of IV-APAP use as a part of an MMA
strategy and should not be interpreted as a
comparison between IV-APAP monotherapy
and IV opioid monotherapy. Of note, patients
included in either study cohort could have
received oral analgesics (see ‘‘Appendix’’,
Table 5 for details on oral analgesics received).
Therefore, it was not possible to ascertain
differences in hospitalization costs directly due
to IV-APAP.
It is of note that a larger proportion of the
study patients who received IV opioid
monotherapy were observed during the earlier
part of the study period (approximately 2/3 of
the patients had index admissions during
2011–2012), possibly indicating the support of
expanded access to and utilization of enhanced
treatment options, including MMA with
IV-APAP, during the latter years of the study
period (2013–2014).
Limitations
This analysis was limited to patients admitted to
those hospitals providing data to the HDD, so
generalizability of the results to all patients
undergoing orthopedic surgery may be limited.
The HDD represents nearly 11% of the
approximately 5,600 registered hospitals in the
US [31]; hospitals in the Northeast are slightly
overrepresented, compared with the universe of
hospitals in the US, as are hospitals with fewer
beds, although institutions in the HDD are
generally the same with regard to patient age
and gender [31, 39]. Additionally, this study
assessed hospitalization costs only and could
not account for healthcare utilization or costs
post-discharge. Additional research is also
needed to characterize mechanisms by which
MMA including IV-APAP may influence
hospitalization costs and other outcomes.
CONCLUSIONS
In this retrospective observational analysis of a
large nationwide hospital database, patients
undergoing TKA, THA, or hip fracture repair
who received IV-APAP as part of postoperative
MMA had significantly lower total
hospitalization costs than did patients who
received IV opioid monotherapy. This cost
difference was driven almost exclusively by
significantly lower medical costs; importantly,
pharmacy costs for the 2 groups were
comparable.
These results suggest that including IV-APAP
in MMA for postoperative pain management for
these common orthopedic surgical procedures
may yield overall cost savings. From a
clinician’s perspective, the inclusion of
IV-APAP as a part of MMA’s treatment
armamentarium has the potential to assist in
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enhancing recovery and delivering more
cost-effective care than IV opioid
monotherapy. From a hospital administrator
or population health decision maker
perspective, MMA may also help reach the
goal of the IHI Triple Aim and support current
practice guidelines or recommendations from
healthcare agencies.
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APPENDIX
See Tables 3, 4, 5.






Arthroplasty, knee, condyle, and plateau;
medial AND lateral compartments,
with or without patella resurfacing
(total knee arthroplasty)




Arthroplasty, acetabular, and proximal
femoral prosthetic replacement (total
hip arthroplasty), with or without
autograft or allograft
27130 Total hip replacement 81.51




Open treatment of posterior or anterior
acetabular wall fracture, with internal
ﬁxation
27226 Open reduction of fracture of
femur without internal ﬁxation
79.25
Open treatment of acetabular
fracture(s) involving anterior or
posterior (1) column, or a fracture
running transversely across the
acetabulum, with internal ﬁxation
27227 Open reduction of fracture of
femur with internal ﬁxation
79.35
– – Open reduction of fracture of
other speciﬁed bone, except
facial bones, without internal
ﬁxation
79.29
– – Open reduction of fracture of
other speciﬁed bone, except
facial bones, with internal
ﬁxation
79.39
Substance abuse disorder – – Drug dependence 304.xx
Substance abuse disorder – – Nondependent other mixed or
unspeciﬁed drug abuse, other,
mixed, or unspeciﬁed drug
abuse
305.90
CPT current procedural terminology, ICD-9-CM international classiﬁcation of diseases, 9th Revision, Clinical Modiﬁcation
432 Adv Ther (2017) 34:421–435
REFERENCES
1. Berwick DM, Nolan TW, Whittington J. The triple
aim: care, health, and cost. Health Aff (Millwood).
2008;27(3):759–69.




3. American Academy of Orthopaedic Surgeons.
Management of hip fractures in the elderly:
Evidence-based clinical practice guideline. http://
www.aaos.org/cc_files/aaosorg/research/guidelines/
hipfxguideline.pdf. 2014. Accessed June 12, 2016.
4. American Academy of Orthopaedic Surgeons.
Current strategies in anesthesia and analgesia for
total knee arthroplasty. J Am Acad Orthop Surg.
2016;24(2):60–73.
5. American Society of Anesthesiologists Task Force
on Acute Pain Management. Practice guidelines for
acute pain management in the perioperative
setting: an updated report by the American
Society of Anesthesiologists Task Force on
Acute Pain Management. Anesthesiology.
2012;116(2):248–73.
6. Barr J, Fraser GL, Puntillo K, et al. Clinical practice
guidelines for the management of pain, agitation,
and delirium in adult patients in the intensive care
unit. Crit Care Med. 2013;41:263–306.
7. Chou R, Gordon DB, de Leon-Casasola OA, et al.
Management of postoperative pain: a Clinical
practice guideline from the American Pain Society,
the American Society of Regional Anesthesia and
Pain Medicine, and the American Society of
Anesthesiologists’ Committee on Regional
Anesthesia, Executive Committee, and
Administrative Council. J Pain. 2016;17(2):131–57.
8. Jarzyna D, Jungquist CR, Pasero C, et al. American
Society for Pain Management Nursing guidelines on
monitoring for opioid-induced sedation and
respiratory depression. Pain Manag Nurs.
2011;12:118–45.
9. Joint Commission. Safe use of opioids in hospitals.
Sentinel Event Alert. 2012;49:1-5. http://www.
jointcommission.org/assets/1/18/SEA_49_opioids_
8_2_12_final.pdf. Accessed June 28, 2016.
10. Joint Commission. Clarification of the pain





11. Hughes RD, ed. Patient Safety and Quality: An
Evidence-Based Handbook for Nurses. 2008.
Rockville, MD: Agency for Healthcare Research
and Quality.
Table 4 Other IV analgesics received by the IV-APAP
group (n = 33,954)










APAP acetaminophen, IV intravenous
Table 5 Oral analgesics received by the IV-APAP group






n % n %
Celecoxib 7789 22.9 16,176 14.7
Hydrocodone bitartrate/
APAP
4225 12.4 18.017 16.3
Tramadol HCL 3812 11.2 2839 2.6
Aspirin 3010 8.9 4874 4.4
Methocarbamol 1416 4.2 5145 4.7
Hydromorphone HCL 1154 3.4 1670 1.5
Morphine sulfate 857 2.5 1480 1.3
Narcotic analgesic
combinations
424 1.2 4367 4.0
Fentanyl 395 1.2 2172 2.0
APAP acetaminophen, HCL hydrochloride, IV
intravenous
Adv Ther (2017) 34:421–435 433
12. Chandrakantan A, Glass PS. Multimodal therapies
for postoperative nausea and vomiting, and pain. Br
J Anaesth. 2011;107(Suppl 1):i27–40.
13. Elia N, Lysakowski C, Trame`r MR. Does multimodal
analgesia with acetaminophen, nonsteroidal
antiinflammatory drugs, or selective
cyclooxygenase-2 inhibitors and
patient-controlled analgesia morphine offer
advantages over morphine alone? Meta-analyses
of randomized trials. Anesthesiology.
2005;103(6):1296–304.
14. Maund E, McDaid C, Rice S, Wright K, Jenkins B,
Woolacott N. Paracetamol and selective and
non-selective non-steroidal anti-inflammatory
drugs for the reduction in morphine-related
side-effects after major surgery: a systematic
review. Br J Anaesth. 2011;106(3):292–7.
15. Duncan CM, Hall Long K, Warner DO, Hebl JR. The
economic implications of a multimodal analgesic
regimen for patients undergoing major orthopedic
surgery: a comparative study of direct costs. Reg
Anesth Pain Med. 2009;34(4):301–7.
16. Buer JK. Origins and impact of the term ‘NSAID’.
Inflammopharmacology. 2014;22(5):263–7.
17. Singla NK, Parulan C, Samson R, et al. Plasma and
cerebrospinal fluid pharmacokinetic parameters
after single-dose administration of intravenous,
oral, or rectal acetaminophen. Pain Pract.
2012;12(7):523–32.
18. Cattabriga I, Pacini D, Lamazza G, et al. Intravenous
paracetamol as adjunctive treatment for
postoperative pain after cardiac surgery: a double
blind randomized controlled trial. Eur J
Cardiothorac Surg. 2007;32(3):527–31.
19. Ketorolac tromethamine injection. USP [prescribing
information]. Schaumberg, IL: Sagent
Pharmaceuticals; 2015.
20. Caldolor (ibuprofen) injection, for intravenous use
[prescribing information]. Nashville, TN:
Cumberland Pharmaceuticals Inc; April 2016.
21. Ofirmev injection [prescribing information].
Hazelwood, MO: Mallinckrodt Pharmaceuticals;
December 2014.
22. Møller PL, Sindet-Pedersen S, Petersen CT, Juhl GI,
Dillenschneider A, Skoglund LA. Onset of
acetaminophen analgesia: comparison of oral and
intravenous routes after third molar surgery. Br J
Anaesth. 2005;94(5):642–8.
23. van der Westhuizen J, Kuo PY, Reed PW, Holder K.
Randomised controlled trial comparing oral and
intravenous paracetamol (acetaminophen) plasma
levels when given as preoperative analgesia.
Anaesth Intensive Care. 2011;39:242–6.
24. Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER,
Groudine SB, Payen-Champenois C. Efficacy and
safety of single and repeated administration of 1
gram intravenous acetaminophen injection
(paracetamol) for pain management after major
orthopedic surgery. Anesthesiology.
2005;102(4):822–31.
25. Wininger SJ, Miller H, Minkowitz HS, Royal MA,
Ang RY, Breitmeyer JB, Singla NK. A randomized,
doubleblind, placebo-controlled, multicenter,
repeat-dose study of two intravenous
acetaminophen dosing regimens for the treatment
of pain after abdominal laparoscopic surgery. Clin
Ther. 2010;32(14):2348–69.
26. Sinatra RS, Jahr JS, Reynolds L, Groudine SB, Royal
MA, Breitmeyer JB, Viscusi ER. Intravenous
acetaminophen for pain after major orthopedic
surgery: an expanded analysis. Pain Pract.
2012;12(5):357–65.
27. Singla NK, Hale ME, Davis JC, et al. IV
acetaminophen: efficacy of a single dose for
postoperative pain after hip arthroplasty: subset
data analysis of 2 unpublished randomized clinical
trials. Am J Ther. 2015;22(1):2–10.
28. McNicol ED, Ferguson MC, Haroutounian S, Carr
DB, Schumann R. Single dose intravenous
paracetamol or intravenous propacetamol for
postoperative pain. Cochrane Database Syst Rev.
2016;23(5):CD007126.
29. Apfel CC, Souza K, Portillo J, Dalal P, Bergese SD.
Patient satisfaction with intravenous
acetaminophen: a pooled analysis of five
randomized, placebo-controlled studies in the
acute postoperative setting. J Healthc Qual.
2015;37(3):155–62.
30. Fingar KR, Stocks C, Weiss AJ, Steiner CA. Most
frequent operating room procedures performed in
U.S. hospitals, 2003–2012. HCUP Statistical Brief
#186. December 2014. Agency for Healthcare
Research and Quality, Rockville, MD. https://
www.hcup-us.ahrq.gov/reports/statbriefs/sb186-
Operating-Room-Procedures-United-States-2012.
pdf. Accessed May 21, 2016.
31. American Hospital Association (AHA). Fast facts on
US hospitals. http://www.aha.org/research/rc/stat-
studies/fast-facts.shtml. 2016. Accessed March 9,
2016.
32. Austin PC. An Introduction to propensity score
methods for reducing the effects of confounding in
observational studies. Multivariate Behav Res.
2011;46(3):399–424.
434 Adv Ther (2017) 34:421–435
33. Lin M, Lucas HC Jr, Shmueli G. Too big to fail: large
samples and the p-value problem. Inf Sys Res.
2013;24:906.
34. Austin PC. Using the standardized difference to
compare the prevalence of a binary variable
between two groups in observational research.
Comm Stat Simulat Comput. 2009;38:1228–34.
35. Malesker MA, Bruckner AL, Loggie B, Hilleman DE.
Intravenous acetaminophen: Assessment of
medication utilization evaluation data in
peri-operative pain management. J Surg.
2015;10(4):257–61.
36. Hansen RN, Pham A, Strassels SA, Balaban S, Wan
GJ. Comparative analysis of length of stay and
inpatient costs for orthopedic surgery patients
treated with IV acetaminophen and IV opioids vs.
IV opioids alone for post-operative pain. Adv Ther.
2016;. doi:10.1007/s12325-016-0368-8.
37. Apfel C, Jahr JR, Kelly CL, Ang RY, Oderda GM.
Effect of I.V. acetaminophen on total hip or knee
replacement surgery: a case-matched evaluation of
a national patient database. Am J Health Syst
Pharm. 2015;72(22):1961–8.
38. Shaffer EE, Pham A, Woldman RL, et al. Estimating
the effect of intravenous acetaminophen for
postoperative pain management on length of stay
and inpatient hospital costs. Adv Ther.
2017;33:2211. doi:10.1007/s12325-016-0438-y.
39. Centers for Disease Control and Prevention.




Adv Ther (2017) 34:421–435 435
